Daily Endocrinology Research Analysis
Today’s most impactful endocrinology papers span immunopathogenesis, AI-enabled imaging diagnostics, and metabolic therapeutics in youth diabetes. A mechanistic study links BAFF-driven non-canonical NF-κB activation in ICOSL+ B cells to type 1 diabetes progression, a deep learning tool personalizes adrenal gland volume reference ranges from low-dose chest CT, and a pediatric cohort suggests GLP-1RA adjunct therapy can reduce weight and insulin needs in youth with type 1 diabetes and obesity.
Summary
Today’s most impactful endocrinology papers span immunopathogenesis, AI-enabled imaging diagnostics, and metabolic therapeutics in youth diabetes. A mechanistic study links BAFF-driven non-canonical NF-κB activation in ICOSL+ B cells to type 1 diabetes progression, a deep learning tool personalizes adrenal gland volume reference ranges from low-dose chest CT, and a pediatric cohort suggests GLP-1RA adjunct therapy can reduce weight and insulin needs in youth with type 1 diabetes and obesity.
Research Themes
- Autoimmune mechanisms in type 1 diabetes
- AI-driven imaging biomarkers for adrenal disorders
- Adjunct metabolic therapies in youth with type 1 diabetes
Selected Articles
1. Innate immune cell-derived BAFF induces non-canonical NF-κB activation to promote inflammatory response of ICOSL
This mechanistic study identifies an ICOSL-expressing B cell subset linked to T1D progression in patient cohorts and mouse models, and shows that innate immune cell–derived BAFF activates non-canonical NF-κB signaling to promote inflammatory responses. Findings reframe T1D pathogenesis to include a BAFF–ICOSL–B cell axis as a potential driver and therapeutic target.
Impact: It delineates a novel B cell–centric pathway in T1D, advancing mechanistic understanding and suggesting new immunomodulatory targets beyond T cells.
Clinical Implications: While not directly practice-changing yet, the BAFF–ICOSL axis could inform biomarker development and guide future trials of BAFF/ICOSL-targeted therapies in T1D.
Key Findings
- Identified an ICOSL-expressing B cell subset associated with T1D progression in human cohorts and mouse models.
- Innate immune cell–derived BAFF triggers non-canonical NF-κB activation, promoting inflammatory responses in ICOSL+ B cells.
- Functional analyses support a BAFF–ICOSL–B cell inflammatory pathway relevant to T1D pathogenesis.
Methodological Strengths
- Integrated human patient cohorts with mouse models to link mechanism to disease progression.
- Mechanistic dissection of BAFF-driven non-canonical NF-κB signaling in B cells.
Limitations
- Sample sizes and effect estimates are not specified in the abstract, limiting appraisal of statistical robustness.
- Clinical translation is untested; no interventional validation of targeting the BAFF–ICOSL axis.
Future Directions: Validate ICOSL+ B cells as biomarkers in prospective T1D cohorts and test BAFF/ICOSL-targeted interventions in preclinical models followed by early-phase clinical trials.
Type 1 diabetes (T1D) is an autoimmune disease resulted from the failure of the immune system to maintain self-tolerance, leading to autoimmune destruction of pancreatic β cells. Although T1D has traditionally been considered as a T cell-driven disease, recent studies have found that B cells play an indispensable role in the pathogenesis. Here, we identified a subset of B cells expressing the inducible T cell co-stimulator ligand (ICOSL), which is associated with T1D progression in cohorts of diabetes patients as well as mouse models. Functional analyses revealed that ICOSL
2. Personalized adrenal gland volume reference ranges and development of a fully automated deep learning screening tool.
Using low-dose chest CT, the authors trained an nnU-Net model to automate adrenal volumetry, then derived individualized reference ranges via quantile regression in a cohort of 18,538 adults. A GMM-based anomaly detector flagged abnormal volumes and was tested in hypertension/diabetes and adrenal hyperplasia datasets, supporting the feasibility of AI-enabled screening.
Impact: This work operationalizes personalized adrenal volumetry at population scale and leverages existing low-dose chest CTs, opening a path to earlier detection of adrenal abnormalities without additional radiation.
Clinical Implications: Automated adrenal volumetry with personalized thresholds could trigger targeted biochemical workups for adrenal disorders (e.g., hyperplasia, incidentalomas) and streamline referrals.
Key Findings
- Developed and validated an nnU-Net-based pipeline to automatically measure adrenal gland volume from low-dose non-contrast chest CT.
- Analyzed 18,538 adults (7,907 healthy) and built individualized adrenal volume reference ranges using multivariable and quantile regression.
- Implemented a GMM-based anomaly detection system tested on hypertension/diabetes and adrenal hyperplasia datasets.
Methodological Strengths
- Very large cohort with distinct datasets for reference building and validation.
- Personalized reference construction using multivariable and quantile regression, coupled with automated segmentation.
Limitations
- Clinical outcomes and diagnostic yield after AI flagging were not reported.
- External multi-center validation across scanners and populations is needed to ensure generalizability.
Future Directions: Conduct prospective multi-center studies linking AI flags to biochemical confirmation and clinical outcomes; assess integration into routine radiology workflows and cost-effectiveness.
OBJECTIVE: This study aims to develop a low-dose CT-based, fully automated deep learning tool for screening adrenal gland volume abnormalities and establishing personalized reference ranges to assist in diagnosing adrenal diseases. METHODS: This study included subjects (≥18 years) who underwent low-dose non-contrast chest CT during routine health check-ups, and three datasets were extracted based on specific criteria: healthy reference, hypertension/diabetes validation, and adrenal abnormality validation. Randomly sampled from these datasets 400 low-dose chest CT images were used to train the nnU-Net-based deep learning model, and 550 images were used for validation. Multivariable regression and restricted cubic splines (RCS) assessed the effects of factors like age, sex, body surface area, and blood markers on adrenal volume. A quantile regression model was used to create individualized reference ranges. A GMM-based anomaly detection system was developed for abnormal volume screening, tested on datasets for hypertension, diabetes, and adrenal hyperplasia. RESULTS: Among the 18,538 adults, 7,907 (42.65 %) were healthy. Adrenal volume ranges ere 3.24 cm CONCLUSION: This study developed individualized adrenal gland volume reference ranges and a low-dose CT-based deep learning tool for automated measurement. The screening tool shows potential to assist in identifying adrenal abnormalities and may provide a methodological basis for future clinical evaluation and application.
3. GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.
In 24 adolescents and young adults with T1D and obesity, 12 months of GLP-1RA therapy produced significant reductions in body weight and BMI, along with improvements in glycemia and lower total daily insulin doses. These real-world data support GLP-1RA as a potential adjunct therapy in pediatric T1D with obesity.
Impact: This is the first longitudinal pediatric report suggesting GLP-1RA may address weight and insulin burden in T1D with obesity, a high-need population amidst the current GLP-1 surge.
Clinical Implications: In specialized pediatric endocrinology settings, GLP-1RA may be considered off-label as adjuncts for T1D with obesity, with careful monitoring and shared decision-making pending prospective trials.
Key Findings
- Twelve months of GLP-1RA therapy led to significant weight loss (-9.49 kg, p<0.0001) and BMI reduction in youth with T1D and obesity.
- Glycemic control improved and total daily insulin doses decreased over time per mixed-effects modeling.
- Most participants used modern diabetes technologies (88% CGM, 67% pumps), supporting feasibility of integration.
Methodological Strengths
- Longitudinal real-world data analyzed with linear mixed-effects models adjusting for age and gender.
- Inclusion of multiple GLP-1RA agents suggests potential class effect.
Limitations
- Small, single-center, retrospective cohort without a control group; heterogeneous GLP-1RA exposure.
- Potential confounding (e.g., lifestyle changes, technology use) cannot be excluded.
Future Directions: Conduct multi-center prospective trials to evaluate efficacy, safety (including DKA risk), and standardized protocols for GLP-1RA adjunct use in pediatric T1D with obesity.
OBJECTIVES: Youth with type 1 diabetes (T1D) and obesity face challenges in achieving optimal glycemic control and experience higher risk for long-term complications. While glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown weight and glycemic benefits in adults with type 1 diabetes, data in pediatric populations are scarce. We report here changes in glycemia, weight, and insulin doses in youth with T1D and obesity prescribed GLP-1RA. METHODS: We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024. Data collected included HbA1c, body weight, BMI, total daily insulin dose (TDD), and continuous glucose monitoring (CGM) metrics. Linear mixed effects models assessed changes over time, adjusting for age and gender. RESULTS: Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p<0.0001), BMI (-3.69 kg/m CONCLUSIONS: This first longitudinal report of GLP-1RA use in youth with T1D and obesity shows clinically meaningful improvements in weight, glycemia, and insulin requirements, supporting the potential role of GLP-1RA as adjunct therapy. Larger prospective studies are needed to guide clinical practice.